Background and Aims:Hepatitis C virus(HCV)infection results in hepatocytic injury with elevation of both alanine aminotransferase(ALT)and aspartate aminotransferase(AST).It remains to be determined if direct-acting an...Background and Aims:Hepatitis C virus(HCV)infection results in hepatocytic injury with elevation of both alanine aminotransferase(ALT)and aspartate aminotransferase(AST).It remains to be determined if direct-acting antiviral treatment can terminate hepatocytic injury following viro-logic response.To this end,we evaluated the pattern and predicting factors of ALT and AST normalization during and after direct-acting antiviral treatment with sustained virologic response at 12 weeks(SVR12).Methods:Single-center ret-rospective study on 115 HCV-infected patients who achieved SVR12 was performed.Results:At treatment week 2,100%and 45.9%showed decline in HCV RNA to<700 IU/mL and undetectable levels,respectively,and this was associated with 85.5%,83.9%and 77.4%ALT normalization,AST nor-malization and ALT and AST normalization.At end of treat-ment,85.6%of patients with baseline elevation of both ALT and AST had normalization of both ALT and AST.At posttreat-ment weeks 12 and 24,90.8%and 94.8%had normalization of both ALT and AST.HCV clearance also resulted in further decline of both ALT and AST in those with baseline<40 IU.Univariate analysis showed baseline Child-Pugh score of<6,model for end-stage liver disease score of<10,HCV geno-type 1,and HCV RNA of<500 IU/mL at treatment week 2 were associated with sustained normalization of both ALTand AST at posttreatment week 12.On multivariate analysis,baseline model for end-stage liver disease score of<10 was significantly associated with normalization of both ALT and AST at posttreatment week 12,independent of baseline Child-Pugh score<6,HCV genotype 1,and HCV RNA of<500 IU/mL at treatment week 2.Conclusions:During direct-acting antiviral therapy,85.5%and 83.9%had nor-malization of both ALTand ASTas early as in week 2,providing;biochemical evidence of hepatocytic injury resolution.Sustained normalization of both ALT and AST was seen in 90.8%at posttreatment weeks 12,and was independently associated with baseline model for end-stage liver disease score of<10.展开更多
文摘Background and Aims:Hepatitis C virus(HCV)infection results in hepatocytic injury with elevation of both alanine aminotransferase(ALT)and aspartate aminotransferase(AST).It remains to be determined if direct-acting antiviral treatment can terminate hepatocytic injury following viro-logic response.To this end,we evaluated the pattern and predicting factors of ALT and AST normalization during and after direct-acting antiviral treatment with sustained virologic response at 12 weeks(SVR12).Methods:Single-center ret-rospective study on 115 HCV-infected patients who achieved SVR12 was performed.Results:At treatment week 2,100%and 45.9%showed decline in HCV RNA to<700 IU/mL and undetectable levels,respectively,and this was associated with 85.5%,83.9%and 77.4%ALT normalization,AST nor-malization and ALT and AST normalization.At end of treat-ment,85.6%of patients with baseline elevation of both ALT and AST had normalization of both ALT and AST.At posttreat-ment weeks 12 and 24,90.8%and 94.8%had normalization of both ALT and AST.HCV clearance also resulted in further decline of both ALT and AST in those with baseline<40 IU.Univariate analysis showed baseline Child-Pugh score of<6,model for end-stage liver disease score of<10,HCV geno-type 1,and HCV RNA of<500 IU/mL at treatment week 2 were associated with sustained normalization of both ALTand AST at posttreatment week 12.On multivariate analysis,baseline model for end-stage liver disease score of<10 was significantly associated with normalization of both ALT and AST at posttreatment week 12,independent of baseline Child-Pugh score<6,HCV genotype 1,and HCV RNA of<500 IU/mL at treatment week 2.Conclusions:During direct-acting antiviral therapy,85.5%and 83.9%had nor-malization of both ALTand ASTas early as in week 2,providing;biochemical evidence of hepatocytic injury resolution.Sustained normalization of both ALT and AST was seen in 90.8%at posttreatment weeks 12,and was independently associated with baseline model for end-stage liver disease score of<10.
